A4250

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

A4250（A-4250，Odevixibat）是一种小分子回肠胆汁酸转运蛋白（IBAT）抑制剂，用于治疗胆汁淤积性肝病，包括进行性家族性肝内胆汁淤积和 NASH。

A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH.Other Indication Phase 3 Clinical.

——

Odevixibat (A4250)(0.01% (w/w) in chow diet; 4 weeks) improves sclerosing cholangitis and significantly reduces serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory and pro-fibrogenic genes and bile duct proliferation in Mdr2-/- mice.In addition, Odevixibat (A4250) significantly reduces bile flow and biliary BA output, which correlates with reduced bsep transcription, while Ntcp and Cyp7a1 are induced. Animal Model:Eight week old Mdr2-/- (Abcb4-/-) mice (model of cholestatic liver injury and sclerosing cholangitis)Dosage:0.01% (w/w) in chow diet Administration: 4 weeks Result:Decreased cholestatic liver and bile duct injury in mice model.

A-4250 | Odevixibat

Membrane Transporter/Ion Channel

ASBT Transporter

ASBT Transporter

Other Indications

Other Disease

501692-44-0

740.931

C37H48N4O8S2

>98% (HPLC)

In Vitro:?DMSO : 166.67 mg/mL (224.95 m)

CC[C@H](NC([C@H](NC(COC1=C(SC)C=C(C2=C1)N(C3=CC=CC=C3)CC(CCCC)(CCCC)NS2(=O)=O)=O)C4=CC=C(O)C=C4)=O)C(O)=O

Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI)

(-20℃)

With Ice Pack

≥ 2 years